CEO Granted 4.06 Million Performance Share Units Tied to Key FDA Approvals
DBVT sits 100% above its 52-week low of $8.3.
Summary
DBV Technologies granted its CEO 4.06 million performance share units, valued at over $67 million, contingent on key FDA approvals for its Viaskin Peanut product.
Key Events · Executive and Board Changes · DBVT
-
CEO Performance Share Unit Grant
The Board approved a grant of 4,060,000 Performance Share Units (PSUs) to CEO Daniel Tassé, effective June 5, 2026. This is in addition to a prior 1.74 million PSU grant on May 5, 2026.
-
FDA Approval Milestones
Vesting of the PSUs is contingent on achieving two performance conditions related to U.S. FDA approval of a Biologics License Application (BLA) for Viaskin Peanut, with a vesting date of July 1, 2028.
-
Significant Potential Dilution
The grant represents a substantial potential future dilution for shareholders, with the PSUs valued at approximately $67.35 million based on the current stock price, if all performance conditions are met.
Analysis · DBVT · Life Sciences
DBV Technologies has granted its CEO, Daniel Tassé, 4.06 million Performance Share Units (PSUs), a substantial equity award. This grant, valued at approximately $67.35 million based on the current stock price, represents significant potential future dilution for existing shareholders. The vesting of these PSUs is directly tied to critical U.S. FDA approvals for the company's Viaskin Peanut product, aligning the CEO's long-term compensation with the achievement of major regulatory milestones. This follows a previous grant of 1.74 million PSUs to the CEO on May 5, 2026, indicating a pattern of significant performance-based equity compensation.
At the time of this filing, DBVT was trading at $16.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $8.30 to $26.19. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.